Bio-TechneTECH +19.35%83 FCF Margin % is 24.91% as of Mar. 2026, which is 11% above its 10-year median of 22.36. GuruFocus rates TECH with a GF Score™ of 83/100 and a GF Value™ of $72.49 (Fairly Valued). The stock has 4 warning signs investors should review. Among 960 Biotechnology companies, Bio-Techne ranks better than 90.42% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bio-Techne's Free Cash Flow for the
three
months ended in Mar. 2026 was $78 Mil. Bio-Techne's Revenue for the
three
months ended in Mar. 2026 was $311 Mil. Therefore, Bio-Techne's FCF Margin % for the quarter that ended in Mar. 2026 was 24.91%.
The historical rank and industry rank for Bio-Techne's FCF Margin % or its related term are showing as below:
TECH'
s FCF Margin % Range Over the Past 10 Years
Min: 19.02 Med: 22.36 Max: 33.07
Current: 22.27
During the past 13 years, the highest FCF Margin % of Bio-Techne was 33.07%. The lowest was 19.02%. And the median was 22.36%.
TECH's FCF Margin % is ranked better than 90.42% of 960
companies
in the Biotechnology industry
Industry Median: -85.21
vs TECH: 22.27
Bio-Techne FCF Margin % Related Terms
Bio-Techne FCF Margin % Historical Data
* Premium members only.
The historical data trend for Bio-Techne's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bio-Techne's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Bio-Techne's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Techne (TECH) has a FCF Margin % of 24.91% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bio-Techne and its competitors. This is 11% above median its historical median of 22.36. Over the past decade, Bio-Techne's FCF Margin % has ranged from 19.02 to 33.07. According to the industry distribution chart, Bio-Techne ranks #92 out of 960 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Bio-Techne's FCF Margin % too high?
Bio-Techne's current FCF Margin % of 24.91% is 11% above median its 10-year median of 22.36. Over the past 10 years, this metric has ranged from a low of 19.02 to a high of 33.07. Based on the distribution chart, Bio-Techne ranks #92 out of 960 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bio-Techne has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's FCF Margin % compare to HALO and IBRX?
According to the Biotechnology industry distribution chart, Bio-Techne ranks #92 out of 960 companies for FCF Margin %. This places Bio-Techne in the top 10% of its industry — outperforming the majority of peers. Historically, Bio-Techne's own FCF Margin % has ranged from 19.02 to 33.07 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bio-Techne and its competitors. Bio-Techne's current FCF Margin % is 24.91%, which is 11% above median its own 10-year median of 22.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Based on GuruFocus' analysis, Bio-Techne (TECH) is currently considered Fairly Valued. The stock's GF Value™ is $72.49, compared to a current price of $70.27 — trading 3.1% below its estimated fair value. The current FCF Margin % is 24.91%, which is 11% above median its 10-year median of 22.36. Bio-Techne's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Bio-Techne (TECH), the current FCF Margin % is 24.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Techne (TECH) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued.
The current stock price of $70.27 is trading 3.1% below its estimated GF Value™ of $72.49.
GuruFocus considers Bio-Techne to be Fairly Valued.
Key valuation signals for TECH:
FCF Margin %: 24.91% (11% above median its 10-year median of 22.36)
GF Value™: $72.49 vs. price of $70.27 (3.1% below fair value)
No single metric tells the full story. See the TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
83GF Score
Get the complete analysis for TECH
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TECH has been successfully added to your 
